KY-05009

• CAT Number: I017145
• CAS Number: 1228280-29-2
• Molecular Formula: C₁₈H₁₆N₄O₂S
• Molecular Weight: 352.41
• Purity: ≥95%
• Target: Stem Cell/Wnt
• IUPAC Name: 2-anilino-5-[(4-methylbenzoyl)amino]-1,3-thiazole-4-carboxamide
• InChI: InChI=1S/C18H16N4O2S/c1-11-7-9-12(10-8-11)16(24)22-17-14(15(19)23)21-18(25-17)20-13-5-3-2-4-6-13/h2-10H,1H3,(H2,19,23)(H,20,21)(H,22,24)
• InChIKey: WCEDGRTWDSHZHF-UHFFFAOYSA-N
• SMILES: CC1=CC=C(C=C1)C(=O)NC2=C(N=C(S2)NC3=CC=CC=C3)C(=O)N

KY-05009(Cat No.:I017145) is a potent ATP-competitive inhibitor of Traf2- and Nck-interacting kinase (TNIK) with a Ki of 100 nM. By targeting TNIK, KY-05009 exerts pharmacological inhibition of TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in lung adenocarcinoma cells. It effectively inhibits the protein expression of TNIK, the transcriptional activity of Wnt target genes, and induces apoptosis in cancer cells. KY-05009 demonstrates promising anti-cancer activity and holds potential for cancer treatment. Furthermore, it inhibits proliferation, induces caspase-dependent apoptosis, and suppresses Wnt signaling-related genes in cancer cells, highlighting its therapeutic implications in cancer therapy and modulation of cellular processes related to tumor progression.

Reference

[1]. Lee Y, et al. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. Oncotarget. 2017 Jun 20;8(25):41091-41101.